
BiotechTV - News Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
May 7, 2025
Chapters
Transcript
Episode notes

BiotechTV - News